Phosphoramidite Market Size to Reach USD 2.45 Billion by 2034, Driven by DNA Synthesis and Gene Therapy Research
The global phosphoramidite market size was valued at USD 1.29 billion in 2025 and is predicted to hit around USD 2.45 billion by 2034, rising at a 7.4% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research.
Ottawa, Jan. 30, 2026 (GLOBE NEWSWIRE) -- The global phosphoramidite market size is calculated at USD 1.38 billion in 2026 and is expected to reach around USD 2.45 billion by 2034, growing at a CAGR of 7.4% for the forecasted period.
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5604
Key Takeaways
- North America accounted for the largest share of the phosphoramidite market in 2024.
- Asia Pacific is expected to grow at the fastest CAGR in the studied years.
- By type, the DNA phosphoramidites segment registered dominance in the market in 2024.
- By type, the RNA phosphoramidites segment is expected to grow at the fastest CAGR in the market during the forecast period.
- By application, the drug discovery & development segment led the market in 2024 and is expected to grow at the fastest CAGR in the market during the forecast period.
- By end-use, the pharmaceutical & biotechnology companies segment dominated the market and is expected to grow at the fastest CAGR in the market during the forecast period.
What is Phosphoramidite?
Phosphoramidite is a chemically activated phosphorus-containing compound widely used in solid-phase synthesis of oligonucleotides, enabling the stepwise formation of DNA and RNA chains through controlled phosphate triester linkages. The phosphoramidite market is growing due to rising demand for synthetic DNA and RNA in genomics, diagnostics, and therapeutic applications. Expanding use of oligonucleotide-based drugs, gene therapies, and RNA technologies is driving consumption. Increased research in biotechnology, advancements in solid-phase synthesis, and growing investment in life sciences and pharmaceutical R&D further support sustained market growth.
What are the Key Drivers in the Phosphoramidite Market?
The key drivers in the market include the increasing use of oligonucleotide-based therapeutics and the rising demand for synthetic DNA and RNA in genomics, diagnostics, and research applications. Growth in mRNA vaccine gene therapy development, expanding pharmaceutical and biotechnology R&D investments, technological advancements in oligonucleotide synthesis, and the increasing number of clinical trials using nucleic acid-based drugs are further accelerating market expansion.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
What are the Ongoing Trends in the Phosphoramidite Market?
- In February 2025, Agilent announced a USD 725 million investment to significantly expand its nucleic acid manufacturing capacity. The expansion targets siRNA, antisense oligonucleotides, and CRISPR guide RNAs, with full GMP-compliant operations expected to be operational by 2026.
- In November 2024, Maravai LifeSciences announced plans to acquire Officinae Bio’s DNA/RNA division, enhancing its mRNA production capabilities and integrating AI-driven processes. The acquisition is expected to be completed by early 2025, strengthening the company’s nucleic acid manufacturing portfolio.
What is the Emerging Challenge in the Phosphoramidite Market?
The emerging challenge in the market is the high cost and complexity of production processes. Strict regulatory requirements, supply chain constraints, and the demand for ultra-pure reagents for therapeutic and research applications further limit scalability and pose obstacles to market expansion.
Regional Analysis
What Made North America Dominant in the Phosphoramidite Market in 2024?
North America dominated the market in 2024 due to its well-established biotechnology and pharmaceutical sectors, advanced research infrastructure, and early adoption of nucleic acid-based technologies. High demand for oligonucleotide therapeutics, mRNA vaccines, and gene-editing applications drove consumption. Strong R&D investment, the presence of leading market players, and supportive regulatory frameworks for nucleic acid production further reinforced the region’s leadership, making it the largest contributor to global phosphoramidite market revenue.
For Instance,
-
In March 2025, the clinical trial landscape for oligonucleotide-based therapies is highly active, with nearly 300 registered studies involving more than 75,000 patients. This highlights the strong momentum in developing and evaluating nucleic acid–based treatments across multiple disease areas.
In the U.S., the phosphoramidite market is advancing as pharmaceutical and biotechnology research expands, increasing demand for high-purity reagents used in DNA and RNA synthesis for diagnostics and therapeutic development. Strong research infrastructure and advanced commercial production support broader adoption in molecular biology and genetic engineering applications.
How did the Asia Pacific Expand at the Fastest Pace in the Market?
Asia Pacific expanded at the fastest pace in the phosphoramidite market due to rapid growth in biotechnology and pharmaceutical manufacturing, rising investment in nucleic acid research, and increasing adoption of oligonucleotide-based therapies. Improving healthcare infrastructure, supportive government initiatives, and expanding clinical trial activity further accelerated market growth. Additionally, the region's cost-efficient production capabilities and growing presence of contract manufacturing organizations strengthened its rapid market expansion.
In China, rapid growth in biotechnology and pharmaceutical R&D is driving rising phosphoramidite use, particularly for oligonucleotide synthesis in gene therapy and diagnostic development. Government investment in life sciences and expanding manufacturing capacity are strengthening market capabilities and fueling sustained demand across research and commercial sectors.
Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting
Segmental Insights
By Type Analysis
How did the DNA Phosphoramidites Segment Dominate the Market in 2024?
The DNA phosphoramidites segment registered dominance in the phosphoramidite market in 2025 due to their widespread use in synthetic DNA production for research, diagnostics, and therapeutic applications. High demand from genomics, PCR, sequencing, and antisense oligonucleotide development drove adoption. Additionally, established synthesis protocols, consistent quality, and strong demand from pharmaceutical and biotechnology companies supported the segment’s leading market position.
The RNA phosphoramidites segment is expected to grow at the fastest CAGR during the forecast period due to the rapid expansion of RNA-based therapeutics, including mRNA vaccines, siRNA, and antisense oligonucleotides. Increasing research in gene silencing and RNA interference, rising clinical trials activity, and growing pharmaceutical investments in RNA technologies are broader therapeutic applications, further supporting accelerated market growth.
By Application Insights
Why Drug Discovery & Development Segment Dominated the Phosphoramidite Market?
The drug discovery & development segment dominated the phosphoramidite market in 2024 due to the extensive use of phosphoramidites in synthesizing oligonucleotides for therapeutic research. Growing focus on nucleic acid-based drugs, expanding clinical pipelines, and rising R&D investments are expected to drive the fastest CAGR during the forecast period. Technological advancements, increased precision medicine efforts, and strong pharmaceutical and biotechnology demand continue to support sustained market growth.
By End-Use Analysis
How did the Pharmaceutical & Biotechnology Companies Segment Dominate the Market in 2024?
The pharmaceutical & biotechnology companies segment dominated the phosphoramidite market in 2024 due to high demand for phosphoramidities in drug discovery, clinical research, and commercial production of oligonucleotide therapeutics. Strong R&D investments, expanding pipelines of nucleic acid- based drugs, and advanced manufacturing capabilities are expected to drive the fastest period. Growing adoption of gene therapies, mRNA technologies, and precision medicine further supports rapid segment growth.
Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership
What are the Recent Developments in the Phosphoramidite Market?
- In August 2025, the 4th Annual Oligonucleotide Analytical Development and CMC Summit is scheduled to be held, bringing together industry experts to discuss advanced analytical approaches for improving quality and efficiency in oligonucleotide synthesis.
- In June 2024, Suven Pharmaceuticals acquired a 67.5% stake in Sapala Organics, an oligonucleotide drug CDMO, for approximately USD 27.5 million. The acquisition strengthened Suven’s capabilities in manufacturing phosphoramidites and other oligonucleotide intermediates and positively impacted investor sentiment, reflected in a notable rise in its share price.
Top Companies and Their Offerings to the Market’s Growth
| Company | Product Offerings | Market Focus | Key Contributions | Application Areas |
| BOC Sciences | High-quality phosphoramidites and custom synthesis services for DNA/RNA synthesis | Research-grade and custom chemistry | Tailored phosphoramidites, including modified and biotinylated products, to support oligonucleotide workflows. | Molecular biology, diagnostics, and synthetic biology research |
| Thermo Fisher Scientific Inc. | Broad portfolio of phosphoramidites, including standard and specialty amidites for oligonucleotide synthesis | Comprehensive life-sciences reagents | Large catalog, custom solutions, scalable support from research to manufacturing | Diagnostics, therapeutic research, genomics |
| Merck KGaA | High-purity phosphoramidites and synthesis reagents | Global reagent supplier | Quality, reliability, and regulatory-compliant chemistry supporting research and commercial synthesis | Pharma R&D, advanced synthesis applications |
| Glen Research | DNA/RNA phosphoramidites, solid supports, and ancillary reagents | Oligonucleotide synthesis specialist | Extensive reagent range and support materials for modifications and labeling | Custom sequence design, research workflows |
| LGC Biosearch Technologies | Oligonucleotide reagents, modified phosphoramidites, and synthesis support | Molecular biology and diagnostic reagents | End-to-end oligo chemistry portfolio and technical support for high-throughput synthesis | Diagnostics, genomics, therapeutic discovery |
Phosphoramidite Market Key Players List
- BOC Sciences
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Glen Research
- LGC Biosearch Technologies
- Biosynth
- BIONEER CORPORATION
- QIAGEN
- PolyOrg, Inc
Browse More Insights of Towards Healthcare:
The global synthetic tissue engineering market size is calculated at US$ 1.51 billion in 2024, grew to US$ 1.72 billion in 2025, and is projected to reach around US$ 5.61 billion by 2034. The market is projected to expand at a CAGR of 14.14% between 2025 and 2034.
The global separation systems for commercial biotechnology market size was estimated at USD 29.57 billion in 2025 and is predicted to increase from USD 31.27 billion in 2026 to approximately USD 56.72 billion by 2035, expanding at a CAGR of 6.84% from 2026 to 2035.
The global humanized mouse and rat model market size is calculated at US$ 278.16 million in 2025, grew to US$ 300.83 million in 2026, and is projected to reach around US$ 608.92 million by 2035. The market is expanding at a CAGR of 8.15% between 2026 and 2035.
The global nanoparticle synthesis system market size is calculated at US$ 0.78 billion in 2025, grew to US$ 0.87 billion in 2026, and is projected to reach around US$ 2.28 billion by 2035. The market is projected to expand at a CAGR of 11.34% between 2026 and 2035.
The global pharmaceutical filtration market size is projected to reach USD 32.51 billion by 2035, growing from USD 14.95 billion in 2025, at a CAGR of 8.08% during the forecast period from 2026 to 2035.
The thermostable vaccine market size stood at US$ 9.27 billion in 2025, grew to US$ 9.96 billion in 2026, and is forecast to reach US$ 19.05 billion by 2035, expanding at a CAGR of 7.47% from 2026 to 2035.
The global gene prediction tools market size is calculated at US$ 237.44 million in 2025, grew to US$ 281.89 million in 2026, and is projected to reach around US$ 1320.67 million by 2035. The market is expanding at a CAGR of 18.72% between 2026 and 2035.
The global biotechnology based chemicals market size was estimated at USD 109.53 billion in 2025 and is predicted to increase from USD 120.09 billion in 2026 to approximately USD 274.93 billion by 2035, expanding at a CAGR of 9.64% from 2026 to 2035.
The global proteinase K market size is calculated at USD 5.23 billion in 2025, grew to USD 5.68 billion in 2026, and is projected to reach around USD 11.87 billion by 2035. The market is expanding at a CAGR of 8.54% between 2026 and 2035.
The global low-input sequencing technologies market is on an upward trajectory, poised to generate substantial revenue growth, potentially climbing into the hundreds of millions over the forecast years from 2026 to 2035.
Segments Covered in the Report
By Type
- DNA Phosphoramidites
- RNA Phosphoramidites
- Labeled Phosphoramidites
- Modifier Phosphoramidites
- Others
By Application
- Drug Discovery & Development
- Diagnostics Development
- Others
End-use
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Others
By Region
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/checkout/5604
Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web: https://www.towardshealthcare.com
Our Trusted Data Partners
Precedence Research | Towards Packaging | Towards Food and Beverages | Towards Chemical and Materials | Towards Dental | Towards EV Solutions | Healthcare Webwire
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
